cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Amylyx Pharmaceuticals Inc
2 own
6 watching
Current Price
$14.91
$-0.97
(-6.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,411.76M
52-Week High
52-Week High
38.32000
52-Week Low
52-Week Low
11.82000
Average Volume
Average Volume
1.12M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,411.76M
icon52-Week High38.32000
icon52-Week Low11.82000
iconAverage Volume1.12M
iconDividend Yield--
iconP/E Ratio--
What does the Amylyx Pharmaceuticals Inc do?
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company s product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Amylyx Pharmaceuticals Inc make?
News & Events about Amylyx Pharmaceuticals Inc.
Business Wire
8 months ago
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the application for conditional marketing authorisation of AMX0035 (sodium...
Business Wire
8 months ago
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that it has completed the negotiation process and entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the terms and conditions under which ALBRIOZA (sodium phenylbutyrate...
Business Wire
9 months ago
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its first quarter 2023 financial results on Thursday, May 11, 2023, following the close of the U.S. financial markets. Amylyx senior management team will host a conference call and audio webcast at 4:30 p.m. ET to...
Business Wire
10 months ago
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that the first participant has been dosed in the HELIOS study, a Phase 2 clinical trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) for the treatment of Wolfram syndrome (WS). HELIOS is an...
Business Wire
10 months ago
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the 22nd Annual Needham Virtual Healthcare Conference. The conference is being conducted in a virtual format, and the presentation will take...
Frequently Asked Questions
Frequently Asked Questions
What is Amylyx Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Amylyx Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Amylyx Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Amylyx Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Amylyx Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Amylyx Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Amylyx Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Amylyx Pharmaceuticals Inc?
plus_minus_icon
What percentage is Amylyx Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Amylyx Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$14.91
$-0.97
(-6.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00